Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview

Lydia A. Mercado,Fernando Gil-Lopez,Razvan M. Chirila,Denise M. Harnois

DOI: https://doi.org/10.3390/diagnostics14040382

IF: 3.6

2024-02-10

Diagnostics

Abstract:Autoimmune hepatitis is an immune-mediated inflammatory condition of the liver of undetermined cause that affects both sexes, all ages, races, and ethnicities. Its clinical presentation can be very broad, from having an asymptomatic and silent course to presenting as acute hepatitis, cirrhosis, and acute liver failure potentially requiring liver transplantation. The diagnosis is based on histological abnormalities (interface hepatitis), characteristic clinical and laboratory findings (increased aspartate aminotransferase, alanine aminotransferase, and serum IgG concentration), and the presence of one or more characteristic autoantibodies. The large heterogeneity of these clinical, biochemical, and histological findings can sometimes make a timely and proper diagnosis a difficult task. Treatment seeks to achieve remission of the disease and prevent further progression of liver disease. First-line therapy includes high-dose corticosteroids, which are later tapered to decrease side effects, and azathioprine. In the presence of azathioprine intolerance or a poor response to the standard of care, second-line therapy needs to be considered, including mycophenolate mofetil. AIH remains a diagnostic and therapeutic challenge, and a further understanding of the pathophysiological pathways of the disease and the implementation of randomized controlled trials are needed.

medicine, general & internal

What problem does this paper attempt to address?

The paper attempts to address the challenges in the diagnosis and treatment of Autoimmune Hepatitis (AIH). Specifically, the paper explores the following aspects:

1. **Clinical Presentation**: The clinical presentation of AIH is diverse, ranging from asymptomatic to acute liver failure, even requiring liver transplantation. This heterogeneity makes timely and accurate diagnosis difficult.

2. **Diagnostic Criteria**: The diagnosis of AIH is based on histological abnormalities (interface hepatitis), characteristic clinical and laboratory findings (such as elevated transaminases and serum IgG levels), and the presence of specific autoantibodies. However, the diversity of these indicators sometimes complicates the diagnosis.

3. **Treatment Regimens**: The goal of AIH treatment is to achieve disease remission and prevent further progression of liver disease. First-line treatment includes high-dose corticosteroids, followed by gradual tapering to reduce side effects, combined with azathioprine. For patients who do not respond well to standard treatment or cannot tolerate azathioprine, second-line treatments such as mycophenolate mofetil should be considered.

4. **Pathophysiological Mechanisms**: Although the etiology of AIH is unclear, its pathogenesis involves immune-mediated liver inflammation. The paper emphasizes the importance of further understanding the pathophysiological pathways of AIH and conducting randomized controlled trials.

5. **Epidemiological Characteristics**: AIH affects people of all ages, genders, races, and ethnicities, but it is more common in females. There are differences in clinical presentation and disease severity among different populations, which may be related to genetic, immune, and environmental factors.

6. **Special Clinical Manifestations**: The paper also discusses overlap syndromes of AIH with other liver diseases (such as primary biliary cholangitis and primary sclerosing cholangitis), drug-induced liver injury, AIH during pregnancy, the relationship between viral hepatitis and AIH, and de novo AIH after liver transplantation.

In summary, the paper aims to provide a comprehensive overview of the current status of AIH diagnosis and treatment, highlighting the challenges in this field and proposing directions for future research.